Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
non-pegylated liposomal doxorubicin
- Development stage
- Phase 2
- Lead developer
- Teva Pharmaceutical
- Modality
- Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Non-pegylated liposomal doxorubicin (NPLD) is a specialized formulation of doxorubicin, an anthracycline chemotherapy drug. It consists of doxorubicin encapsulated within liposomes (150-250 nm) formed by a lipidic bilayer of acidic egg phosphatidylcholine and cholesterol in a 55:45 ratio. This formulation optimizes doxorubicin's toxicity profile while maintaining its therapeutic efficacy by increasing drug diffusion in tumor tissues and reducing it in normal tissues. NPLD significantly reduces cardiotoxicity compared to conventional doxorubicin and avoids the hand-foot syndrome associated with pegylated liposomal doxorubicin.
- Brand names
- Myocet
- Other names
- NPLD
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on non-pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on non-pegylated liposomal doxorubicin.